YUYuta Ushida

Yuta Ushida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuta Ushida has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Gen Sugawara

    Department of Surgery, Toyota Kosei Hospital, Toyota, Aichi, Japan

    5 shared publications
  • Masaya Inoue

    Department of Surgery, Toyota Kosei Hospital, Toyota, Aichi, Japan

    5 shared publications
  • Yoriko Yamashita

    Department of Pathology, Toyota Kosei Hospital, Toyota, Aichi, Japan

    5 shared publications
  • Akio Saiura

    Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

    2 shared publications
  • Atsushi Oba

    Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

    2 shared publications
  • Hidenari Goto

    Department of Surgery, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Aichi, 446-8602, Japan

    2 shared publications

Latest Publications

  • Open Access

    Robotic Simultaneous Hepatectomy and Distal Pancreatectomy as Conversion Surgery for Metastatic Pancreatic Neuroendocrine Tumor

    by Masakazu Yamaguchi, Yuta Ushida, Yoriko Yamashita, Takeru Itoi, Masaya Inoue, Gen Sugawara

    INTRODUCTION: Systemic therapies have improved outcomes in patients with advanced pancreatic neuroendocrine tumors (PanNETs), and somatostatin analogs are recommended as first-line treatment options for selected patients with advanced disease. However, reports on conversion surgery for PanNETs with multiple liver metastases that are initially not amenable to upfront curative-intent resection remain limited, and robot-assisted simultaneous pancreatic and liver resections are rarely described.CASE PRESENTATION: A 71-year-old woman was incidentally diagnosed with multiple liver nodules by abdominal ultrasonography. Contrast-enhanced CT revealed a calcified tumor in the pancreatic tail with enlarged regional lymph nodes, whereas the liver lesions were better delineated by contrast-enhanced MRI, including a lesion adjacent to the middle hepatic vein. Percutaneous US-guided biopsy of a superficial liver lesion confirmed a well-differentiated neuroendocrine tumor (NET) G2. The patient was diagnosed with a nonfunctioning PanNET with 4 liver metastases, including 1 adjacent to the middle hepatic vein; therefore, complete parenchyma-sparing resection was initially considered infeasible. Transcatheter arterial chemoembolization was performed as locoregional therapy to control the dominant liver lesion supplied by the hepatic artery A5. Systemic lanreotide therapy was administered for approximately 2 years, with mild cutaneous toxicity. Follow-up imaging demonstrated marked regression of the liver metastases: 1 lesion shrank, and the others disappeared, whereas the primary pancreatic tumor and regional lymph node metastases persisted. Therefore, curative-intent conversion surgery was planned, and robot-assisted simultaneous hepatectomy of the residual liver lesion (segment 5) and distal pancreatectomy with lymph node dissection were performed using 5 ports. The operative time was 8h 2 min, and the blood loss was 5 mL. Postoperatively, a minor pancreatic fistula developed and resolved with drainage. The patient was discharged on POD 35. Pathological examination revealed scarred liver metastasis, whereas the pancreatic tumor and 4 metastatic lymph nodes remained viable, corresponding to NET G1 (Ki-67 index, 1%). The patient remained recurrence-free at 15 months postoperatively.CONCLUSIONS: Even in patients with PanNETs and liver metastases, who are initially considered unsuitable for upfront resection, a sustained response to medical therapy can enable curative-intent conversion surgery. Timely surgical consideration is essential, and robot-assisted simultaneous pancreatectomy and hepatectomy may be a feasible strategy for selected patients.

  • Open Access

    Tumor Mutational Burden–High Intrahepatic Cholangiocarcinoma Presenting with Solitary Brain Metastasis: A Case of Precision Oncology

    by Takahiro Maehata, Yuta Ushida, Gen Sugawara, Yoriko Yamashita, Masaya Inoue

    INTRODUCTION: Brain metastasis from intrahepatic cholangiocarcinoma (ICC) is a rare condition with a poor prognosis, and no standard treatment has been established. This report aims to present a case of solitary ICC brain metastasis successfully treated with a multimodal approach guided by comprehensive genomic profiling (CGP).CASE PRESENTATION: A 64-year-old man, who had undergone a left hepatectomy for ICC 15 months prior, presented with recent memory difficulties. A brain MRI revealed a solitary 39-mm ring-enhancing mass in the left temporal lobe. The patient underwent surgical resection of the brain tumor, and histological examination confirmed the lesion was a metastasis from the primary ICC. Postoperatively, he received systemic therapy consisting of gemcitabine, cisplatin, and durvalumab. CGP on the resected brain specimen revealed a high tumor mutational burden status (23 mutations/Mb) and microsatellite stability. At the 8-month follow-up after the craniotomy, the patient remains disease-free with no signs of recurrence.CONCLUSIONS: This case suggests that an integrated approach, combining aggressive local therapy with systemic immunotherapy informed by biomarkers, can achieve a favorable outcome in selected patients with ICC. The identification of a high tumor mutational burden was crucial in guiding treatment and supports its potential as a predictive biomarker. This precision oncology strategy may improve the poor prognosis associated with this condition.

  • Optimizing indocyanine green positive staining with total liver volume-normalized dosing in robotic hepatectomy: an image-based analysis

    by Yuta Ushida, Gen Sugawara, Yoriko Yamashita, Masaya Inoue

    Indocyanine green (ICG) positive staining aids tumor localization in robotic hepatectomy; however, ICG dose and timing remain heterogeneous. We sought to optimize preoperative dosing using total liver volume (TLV)-normalized doses and an image-derived tumor-to-normal fluorescence ratio (TNR), and relate TNR to intraoperative tumor identification. This single-center observational study analyzed 26 consecutive, surface-adjacent hepatic lesions that underwent robotic hepatectomy. ICG was administered intravenously at noon on day − 1. Firefly® images were captured; a prespecified FIJI pipeline extracted the green channel and computed TNR as mean tumor region of interest (ROI) intensity/mean liver ROI intensity. Quadratic regression modeled TNR against TLV-normalized dose (mg/L), adjusting for ICG elimination rate constant and tumor diameter; parametric bootstrap (2,000) yielded the optimum and 95% confidence interval (CI). Receiver operator characteristic analysis assessed identification using prespecified TNR ≥ 2.0. Fluorescence identified 23/26 lesions (88%). The median TNRs were 2.60 (interquartile range 2.28–3.01) and 1.75 (1.38–1.80) in identified and non-identified tumors, respectively (p = 0.005). TLV-normalized modeling exhibited an inverted-U dose–response (quadratic p = 0.006); the optimum was 6.80 mg/L (95% CI 5.80–8.12). The mg/kg optimum was 0.10 mg/kg, and model fit favored TLV over mg/kg (difference in corrected Akaike’s information criterion, 4.9). TNR discriminated identification well (area under the curve, 0.96) at TNR ≥ 2.0. A single day − 1 dose targeting 6.8 mg/L by TLV maximizes fluorescence contrast; TNR ≥ 2.0 is a practical visibility benchmark. A simple bedside rule—dose (mg) = 6.8 × TLV (L)—offers a patient- and organ-informed protocol for prospective validation and multicenter standardization.


  • Open Access

    Hepatocolic fistula in hepatocellular carcinoma treated with atezolizumab–bevacizumab: a case report on successful salvage hepatectomy

    by Kota Ishida, Yuta Ushida, Takayuki Minami, Yoriko Yamashita, Masaya Inoue, Takehiro Kato, Ei Sekoguchi, Yasuhiro Kurumiya, Gen Sugawara

    Combined treatment with atezolizumab (ATZ) and bevacizumab (BV) is the first-line therapy for unresectable advanced hepatocellular carcinoma (HCC). We report a rare case of hepatocolic fistula during ATZ + BV therapy, successfully treated with salvage hepatectomy. A 72-year-old man with advanced HCC underwent treatment with ATZ + BV. After seven cycles, he presented with abdominal pain. Imaging revealed ascites and free air, leading to an emergency laparotomy, where panperitonitis was diagnosed. Despite lavage and drainage, postoperative fever persisted. Further imaging identified a liver abscess, requiring emergency ultrasound-guided percutaneous drainage. Contrast studies confirmed a hepatocolic fistula. The patient underwent ileostomy for abscess management, followed by extended posterior sectionectomy and right hemicolectomy on Day 25. He was discharged 37 days after final surgery without complications.


  • Open Access

    Cholangiolocarcinoma with Ductal Plate Malformation Pattern: A 6-Year Follow-Up

    by Yuta Ushida, Gen Sugawara, Takayuki Minami, Yoriko Yamashita, Masaya Inoue

    INTRODUCTION: Cholangiolocarcinoma (CLC) with ductal plate malformation (DPM) is a rare primary liver cancer originating from the canals of Hering. It often exhibits intermediate behavior between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Diagnosing CLC with DPM is challenging due to overlapping imaging features with other liver malignancies.CASE PRESENTATION: An 82-year-old man under surveillance for bladder cancer was incidentally found to have a liver nodule in segment 8. Over 6 years, the lesion grew from 10 mm to 41 mm and showed dynamic changes on imaging. Despite two inconclusive biopsies, a diagnosis of CLC with DPM was confirmed after a third biopsy and consultation with a specialized institution. The patient underwent a right hepatectomy, and pathological examination confirmed CLC with DPM. No evidence of recurrence was observed 19 months post-surgery.CONCLUSIONS: This case underscores the importance of long-term follow-up and a multidisciplinary approach in managing rare hepatic malignancies. The clinical course provides valuable insights into the progression of CLC with DPM and may aid in diagnosing similar challenging cases.


  • Conversion surgery for recurrent hepatic angiosarcoma after systemic chemotherapy with paclitaxel

    by Yuta Ushida, Takafumi Sato, Tomotaka Kato, Yasuyuki Shigematsu, Hiromichi Ito, Takeshi Suzuki, Yosuke Inoue, Yoshihiro Ono, Atsushi Oba, Yu Takahashi

    A 67-year-old man presented with hemorrhagic shock due to the rupture of hepatic tumor and underwent emergency partial resection of the right liver. Pathological examination revealed hepatic angiosarcoma with involvement in its surgical margin. Six months after the operation, disease recurrence was detected, and he was referred to our hospital for second opinion. CT revealed tumors at the liver cut surface and left lateral segment. The tumor at the liver cut surface abutted to the common bile duct and the portal vein. The tumor was deemed unresectable, and systemic chemotherapy with 4 courses of weekly paclitaxel was given with excellent response. Then, we performed partial liver resection of S4 and S1 with remnant right liver and middle hepatic vein, and wedge resection for the metastatic lesion of segment 3 as a conversion surgery. He developed a grade B bile leakage postoperatively and was discharged on postoperative day 28. He remained disease free for 8 months after the operation.


  • High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment

    by Yuta Ushida, Yuta Ushida, Yosuke Inoue, Yosuke Inoue, Hiromichi Ito, Hiromichi Ito, Atsushi Oba, Atsushi Oba, Yoshihiro Mise, Yoshihiro Mise, et al.


  • Open Access

    Poorly differentiated adenocarcinoma with signet-ring cells in duodenal papilla: a case report

    by Yuta Ushida, Kiyoshi Hiramatsu, Satomi Saeki, Takeshi Amemiya, Hidenari Goto, Toshiyuki Arai

    An 82-year-old woman with common bile duct (CBD) dilatation observed during routine ultrasonography was referred to our hospital. Preliminary blood tests revealed elevated levels of hepatobiliary enzymes. Computed tomography (CT) scan showed lower bile duct wall thickening and enhancement. Esophagogastroduodenoscopy revealed mildly swollen papilla of Vater, without ulceration. Endoscopic retrograde cholangiography demonstrated that the CBD was grossly dilated with a constriction in the lower part. The final diagnosis indicated poorly differentiated adenocarcinoma of duodenal papilla with signet-ring cells; pT3N0M0, stage IIA (Unio Internationalis Contra Cancrum, 7th edition), for which subtotal stomach-preserving pancreaticoduodenectomy (SSPPD) was performed. This case is quite rare, and the surgery resulted in a desirable outcome. The patient has been disease-free for 5 years since the surgery.


  • Open Access

    Long-term survival of a patient with advanced gastric cancer with paraaortic lymph node metastasis who attained pathological complete response after S-1/CDDP chemotherapy: A case report

    by Yuta Ushida, Kiyoshi Hiramatsu, Satomi Saeki, Takeshi Amemiya, Hidenari Goto, Toshiyuki Arai

    Gastric cancer with paraaortic lymph node (PAN) metastasis have unfavorable prognosis. There are no evidence-based preoperative chemotherapy regimens available. A 62-year-old female was diagnosed with advanced gastric cancer and PAN metastasis. We attempted S-1/CDDP chemotherapy in six coursed and total gastrectomy as well as systematic dissection of regional lymph nodes and PAN. Histologically, no cancerous cells were detected in specimens. The patient has been disease-free for 5 years since the surgery. Long-term survival case of gastric cancer with PAN metastasis attaining pathologically complete response is extremely rare. It is possible that preoperative S1/CDDP with surgery might be a standard treatment strategy for gastric cancer with PANs. We report herein a rare case of gastric cancer with PAN metastases who achieved a 5-year survival after S-1/CDDP chemotherapy and surgery.